Core Facilities Munich

Proteomics Facility

© Bernhard Küster/ Technische Universität München

The Core Facility Proteomics at the DKTK Partner site comprises five high-end mass spectrometers, several liquid chromatography systems and terabyte scale computing infrastructure.

The range of supported applications span quantitative protein expression profiling of human and animal tissues, tumors, cell lines and body fluids, dynamic analysis of post-translational modifications, protein-protein interactions, drug target identification, drug mechanism of action analysis and many more. We can offer discovery type proteomic experiments using multidimensional chromatography coupled to the latest Orbitrap technology as well as targeted assays using parallel reaction monitoring. All major quantification workflows are established in the laboratory including SILAC, TMT and a range of label-free analysis. We typically work on the basis of scientific collaboration in which we engage our expertise along the entire path from experiment design through to data acquisition and bioinformatic analysis.


Prof. Dr. Bernhard Küster

Chair of Proteomics and BioanalyticsTechnische Universität München

Emil Erlenmeyer Forum 5
85354 Freising

Leukemia Genomics Facility

© angellodeco /

Genetic characterisation plays a central role for diagnostics, treatment selection and prognostication in patients with leukemia. In close cooperation with local and DKTK partners, we support DKTK scientists exploring the biology and pathogenesis of leukemia.

Our aim is to develop innovative techniques for leukemia diagnostics. Our location at the Ludwig-Maximilians-Universität München (LMU) in the Department of Hematology and Oncology provides a close collaboration with the clinic and translational research groups. We have access to a large number of well-annotated patient specimens that have been collected at our routine diagnostics laboratory (Laboratory for Leukemia Diagnostics).


MiSeq personal sequencer © AG Spiekermann

Our facility can provide the following services to DKTK-affiliated groups:

Genetic characterization of human tissue specimens (primarily peripheral blood and bone marrow) using a variety of approaches including

  • Metaphase and molecular cytogenetics
  • Conventional molecular genetics (Sanger sequencing, fragment analysis and qPCR; various assays established for recurrent mutations in hematopoietic neoplasms)
  • Targeted next-generation sequencing (established panels of recurrently mutated genes in myeloid and lymphoid neoplasms)
  • Whole-exome and whole-genome sequencing
  • Single-cell genotyping


Analyse rekurrenter Genmutationen in 664 AML-Patienten mittels ‘targeted sequencing’ © AG Metzeler

Our main areas of research focus on the following topics

  • Genetic characterisation of myeloid neoplasias
  • Evaluation of novel prognostic and predictive markers in leukemia
  • New therapeutic targets in leukemias
  • Identification of markers for minimal residual disease (MRD)
  • Research on clonal evolution of leukemia

Core facility members: Prof. Dr. Karsten Spiekermann, PD Dr. Klaus Metzeler, PD Dr. Tobias Herold, PD Dr. Philipp Greif, Dr. Sebastian Vosberg, Sebastian Tschuri


Prof. Dr. Karsten Spiekermann
Marchioninistr. 15
81377 München

Xenograft mouse model of acute leukemias

The Core Facility “Xenograft mouse model of acute leukemias” studies primary patients´ tumor cells growing in mice, performs preclinical treatment trials and molecular studies on basic disease biology.

In vivo bioluminescence imaging (BLI) allows reliable and sensitive follow-up of preclinical treatment trials © AG Jeremias

The core facility offers:

  • engrafting and amplifying primary tumor cells from patients with ALL or AML as patient-derived xenografts (PDX) in mice
  • biobank of re-transplantable PDX samples for in vitro studies, >50 for ALL and >10 for AML
  • genetic engineering in PDX (GEPDX) cells for overexpression of transgenes
  • preclinical in vivo treatment trials monitored by bioluminescence in vivo imaging
    • quantifying treatment responses as early as 4 days after treatment
    • covering all disease stages including minimal residual disease
    • focusing on challenging sub-populations such as dormant stem cells

More information on the Xenograft Facility München

Characteristics of AML PDX samples that were established within the first DKTK funding period © AG Jeremias



Prof. Dr. Irmela Jeremias
Marchioninistraße 25
81377 München

Radiochemistry Synthesizer // All-In-One // Trasis

The synthesizer merges in a single integrated instrument a synthesizer and a HPLC with reformulation capability, which allows implementing both very simple and the most complex radiochemistry. If there is a need to evolve towards more complex tracers, the synthesizer can be upgraded to a different configuration model. The synthesizer includes 30 valves, HPLC, multiple radioactivity, and UV detection for GMP compliant routine production of 18F tracers and /or for R&D.

Das All-In-One Synthesemodul (Fa. TRASIS) in einer Blei-abgeschirmten Synthesezelle (einer sog. „Heisszelle“, Ansicht bei geöffneter Zellentür) in einem Reinraum der Radiopharmazie © AG Bartenstein


Dr. Franz J. Gildehaus
089 4400 69944

Prof. Dr. Peter Bartenstein
089 4400 74611

Location of device

LMU Klinkum, Campus Großhadern, Radiopharmacy Center, Building BT028, Marchioninistrasse 15, 81377 München


In the synthesis module, a sample is equivalent to a synthesis run. The cost of doing so varies greatly depending on the complexity of the chemical synthesis to be performed, how expensive the starting components are, and how the GMP requirements are defined. Normally the costs / synthesis are between 800 € and 2.600 €.


Production of 18F-labeled compounds for in vivo PET imaging. These include:
- Radiofluorinations of small molecules, peptides and biomolecules
- development of labeling strategies
- automation of radiosynthesis
- GMP-compliant implementation

Cell Imaging Multi-Mode Reader // Cytation 1 // Biotek

Cytation 1 © AG Theurich

Cytation™ 1 Cell Imaging Multi-Mode Reader combines fluorescence and high contrast brightfield imaging with conventional multi-mode detection. This design provides both quantitative phenotypic cellular information with well-based quantitative data. Cytation 1's multi-mode detection module includes high sensitivity filter-based fluorescence and a monochromator system for UV-Vis absorbance. For long-term measurements the device is able to control temperature, CO2 and O2. The reader is also equipped with an injector that allows imaging of immediate cell responses upon compound exposure.



Prof. Dr. Sebastian Theurich
Medizinische Klinik III, LMU Klinikum 
Marchioninistr. 25, 81377 München

Prof. Dr. Michael von Bergwelt
Medizinische Klinik III, LMU Klinikum
Marchioninistr. 25, 81377 München

Location of device

Genzentrum LMU
AG Theurich / AG Bergwelt
Feodor-Lynen-Str. 25, 81377 München


on request


Monochromator: 6- to 384-well plates /// Filters: 6- to 1536-well plates /// Imaging: 6- to 1536-well plates /// Microscope slides, Petri and cell culture dishes, cell culture flasks (T25), counting chambers (hemocytometer) /// Take3 Micro-Volume Plates


Digital Single Molecule Quantification // nCounter Sprint // NanoString Technologies

The nCounter technology allows direct quantification of up to 800 targets in a single assay without the necessity of amplifying target molecules. Possibility to measure mRNA, miRNA, lncRNA, dsDNA, und ssDNA (pre-designed or customized code sets available; multiple samples can be multiplexed) in a variety of specimens (tissue biopsies, blood, bone marrow, etc.). No library preparation or sophisticated pre-analytical processing required.

nCounter © NanoString Technologies


Michael Heide
Medizinische Klinik III, ELLF, LMU Klinikum

Prof. Dr. Oliver Weigert
Medizinische Klinik III, ELLF, LMU Klinikum

Location of device

Experimentelle Leukämie- und Lymphom-Forschung (ELLF)
Max-Lebsche-Platz 30, 81377 München

Service & Costs

Technical support via Weigert lab
User bears the cost of consumables, currently no user fee applied

Automated Quantitative Pathology Imaging System // Vectra® Polaris™ // Perkin Elmer

Vectra® Polaris™ © AG Jung

State of the art multispectral imaging to detect and measure multiple biomarkers within a single tissue.







Prof. Dr. Martina Rudelius

Dr. Peter Jung

Location of device

Institut für Pathologie der LMU München, Campus Innenstadt
Thalkirchner Str. 36, 80337 München

Service & Costs

Basic material: FFPE tissue sections stained with up to 6 established antigens and using OPAL dyes

Costs: on request

Bioluminescence tomography // MuriGlo // Xstrahl

MuriGlo is an in vivo optical imaging system for bioluminescence tomography. It can be used as stand-alone-imaging device or in combination with the existing conebeam-CT-platform for bioluminescence imaging in small animal models (preferentially in mice).

MuriGlo © Xstrahl


Prof. Dr. Kirsten Lauber
Moleculare Oncology, Department of Radiation Oncolgoy

Location of device

LMU Klinikum, Campus Großhadern
Animal facility of the Department of Radiation Oncology

Service & Costs

Basic material: small animal models with bioluminescence features

Service: bioluminescence tomography imaging (+/- conebeam CT scanning), consulting for animal experimentation proposals

Costs: on request; one sample represents one bioluminescence tomography scan of one animal

Pre-clinical CT-Scanner // X-Cube // Molecubes

X-Cube © AG Mayerle, Bartenstein

The X-Cube is a high-throughput x-ray CT-scanner for pre-clinical mouse and rat models. The CT imaging procedure is very fast and gives images of the complete animal body at extremely low dosages and with an excellent soft tissue contrast. Advanced workflows such as gated and dynamic contrast enhanced imaging can be achieved in a functional and integrated set up.





Dr. Ivonne Regel

Prof. Dr. Sybille Ziegler

Location of device

LMU Klinikum, Campus Großhadern
Preclinical Imaging Lab

Service & Costs

Basic material: small animal models (mouse or rat) with an approve health report

Costs: on request